[Treatment of diabetic neuropathy].
Diabetic polyneuropathy is a complication, that affects most patients with longstanding diabetes mellitus, deteriorating their quality of life. In the last few years, new therapeutic approaches have been developed that can improve symptoms and neurologic function, and which may prevent and in some cases stop nerve damage, and even, promote nerve fiber regeneration. These treatments are supported by several investigations in animals and humans: a) thigh glycemic control (insulin), b) aldose reductase inhibition (tolrestat), c) prevention of protein glycation (amino-guanidine), d) improvement of nerve ischemia (vaso-dilators, gamma-linolenic acid), and e) administration of neurotrophic factors (gangliosides). Most evidence support the usefulness for glycemic control. Early treatment is suggested, because marked nerve fiber loss is present in advanced neuropathy.
Frati-Munari
A C
AC
Departamento de Medicina Interna, Hospital de Especialidades Centro Médico La Raza.
Ariza-Andraca
C R
CR
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003929:Diabetic Neuropathies / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005732:Gangliosides / Q000627:therapeutic use; D006031:Glycosylation; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D017965:gamma-Linolenic Acid / Q000627:therapeutic use
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D005732:Gangliosides; D006146:Guanidines; D007328:Insulin; D009281:Naphthalenes; D014665:Vasodilator Agents; C040550:tolrestat; D017965:gamma-Linolenic Acid; D000449:Aldehyde Reductase; C004479:pimagedine
Tratamiento de la neuropatía diabética.